Compare AbbVie Inc (ABBV) vs Warner Music Group Corp (WMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Warner Music Group Corp — how do they compare? AbbVie Inc trades at $253.4 (market cap $449.91B), while Warner Music Group Corp trades at $28.97 (market cap $14.83B). The key difference: AbbVie Inc is far larger — about 30.3× Warner Music Group Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | WMG | |
|---|---|---|
Market Cap | $449.91B | $14.83B |
Sector | Health | Media |
52-Week High | $261.07 | $34.72 |
52-Week Low | $184.85 | $23.65 |
Enterprise Value | $513.38B | $19.03B |
Dividend Yield | 2.72% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Warner Music Group (WMG) trades at $28.44, up 0.57% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.35, beating expectations, and announced the acquisition of Sureel AI to strengthen IP management. Financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Valuation ratios include a P/E of 32.62 and P/S of 2.01, with a consensus analyst price target of $40.40 indicating significant upside potential.
WMG presents a mixed outlook: strong analyst support (66.7% buy ratings) and strategic AI investments offer growth opportunities, but bearish technicals, declining net margins, and competitive pressures pose risks. The stock's current price near support at $27 suggests cautious investor sentiment, with earnings consistency and margin improvement key to unlocking upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
